Rhythm Pharmaceuticals (RYTM) EBITDA Margin (2021 - 2026)
Rhythm Pharmaceuticals (RYTM) reported EBITDA Margin of 90.5% for Q1 2026, up 6493.0% year-over-year from 1.37% in Q1 2025, and down 10.09% quarter-over-quarter from 82.2% in Q4 2025.
Rhythm Pharmaceuticals (RYTM) EBITDA Margin (2021 - 2026) Analysis & Trends
Rhythm Pharmaceuticals (RYTM) has 6 years of EBITDA Margin data on file, last reported at 90.5% in Q1 2026.
- EBITDA Margin for Q1 2026 came in at 90.5%, up 6493.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 91.82% (up 3710.0% YoY), and the FY2025 annual result was 106.81%, up 9665.0% from the prior year.
- EBITDA Margin fell to 90.5% in Q1 2026 per RYTM's latest filing, from 82.2% in the prior quarter.
- Over five years, EBITDA Margin peaked at 523.15% in Q4 2022 and troughed at 3517.42% in Q1 2022.
- A 5-year average of 406.3% and a median of 155.43% in 2025 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2022 and 2023: EBITDA Margin jumped 9476258 bps in 2022, then tumbled 69343 bps in 2023.
- A 5-year view of EBITDA Margin shows it stood at 523.15% in 2022, then slumped by 133 bps to 170.28% in 2023, then soared by 42 bps to 98.63% in 2024, then rose by 17 bps to 82.2% in 2025, then fell by 10 bps to 90.5% in 2026.
- Business Quant data shows RYTM's EBITDA Margin at 90.5% in Q1 2026, 82.2% in Q4 2025, and 102.64% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Rhythm Pharmaceuticals | 6.59 Bn | 6.25 Bn | 52.96 Mn | -90.50% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -90.50% |
| Dec 31, 2025 | -82.20% |
| Sep 30, 2025 | -102.64% |
| Jun 30, 2025 | -93.39% |
| Mar 31, 2025 | -155.43% |
| Dec 31, 2024 | -98.63% |
| Sep 30, 2024 | -131.98% |
| Jun 30, 2024 | -139.20% |
| Mar 31, 2024 | -538.71% |
| Dec 31, 2023 | -170.28% |
| Sep 30, 2023 | -195.31% |
| Jun 30, 2023 | -242.46% |
| Mar 31, 2023 | -458.03% |
| Dec 31, 2022 | 523.15% |
| Sep 30, 2022 | -916.60% |
| Jun 30, 2022 | -497.42% |
| Mar 31, 2022 | -3,517.42% |
| Dec 31, 2021 | -2,806.22% |
| Sep 30, 2021 | -4,303.50% |
| Jun 30, 2021 | -14,756.20% |